Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
INTERVENTIONAL
2005-02-28
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCT
NCT02053779
Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation
NCT00633347
GNRH Agonist Trigger and Modified Luteal Phase Adding a Bolus of GnRHa at the Time of Implantation: a RCT
NCT03039049
Impact of Gonadotrophin Releasing Hormone Analogues on Oocyte and Embryo Quality
NCT03139474
Administration of GnRH Antagonist to Oocyte Donation Recipients
NCT00635258
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tryptorelin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Bilateral tubal patency confirmed by hysterosonography
* Normal ultrasound scan of uterus and ovaries
* Normal day 3 basal hormones
* Motile sperm count after capacitation ≥ 3 mill/ml
Exclusion Criteria
* Polycystic ovary syndrome
* Uterine disease (polyps, myomas and müllerian diseases)
18 Years
38 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Valenciano de Infertilidad, IVI VALENCIA
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jose Bellver
Gynecologist IVI Valencia
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose Bellver, MD
Role: PRINCIPAL_INVESTIGATOR
Instituto Valenciano de la Infertilidad
Elena Labarta, MD
Role: PRINCIPAL_INVESTIGATOR
Instituto Valenciano de Infertilidad
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Valenciano de Infertilidad Spain
Valencia, Valencia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VLC-JB-0205-307-9
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.